Drs. Can prescribe things that do not require prescriptions thereby by solving the reimbursement issue for their patient's ...., problem solved! I do it all the time.
I've been reading this board for a couple of weeks and can't find anything that hasn't been repeated Ad nauseam. That being said, I believe this will be the best investment I've ever made.
Source: NY Mag
Bottom Line. Regardless whether MannKind has been a victim of Wall Street's manipulation is still up to the jury, it is imperative for shareholders to realize that highly successful investors like Warren Buffett or Peter Lynch are not nervous by temporarily declining in share price. Also, we commend the intelligent and responsible efforts by shareholders and responsible citizens.
Contrary to the negativity preaching by Mr. Market regarding the recent Partnership announcement with Sanofi, investors should be cognizant that MannKind indeed scored a major victory for millions of patients and shareholders with the partnership announcements because Sanofi is a highly dominant global commercial partner. MannKind also inked a deal with Amphastar – the stellar recombinant insulin supply partner.
Unlike many microcaps and/or risky speculations promoting by Mr. Market like AntriBio, Astrom Bioscience, Cynapsus, Immune Pharmaceutical, or Elite Pharmaceuticals, MannKind's risks have also been deleveraged or greatly lowered, because Afrezza already received positive phase 1 through phase 3 trial data, strong votes of confidence from the FDA Advisory Committee (ADCOM) experts, approval by the FDA, and secured the most-dominant global diabetes leader as its partner. Given that Sanofi already has a sales and marketing teams for the top selling basal insulin drug, Lantus, there is no need to build a new team from scratch. The current sales/marketing team could introduce Afrezza to their strong existing relationship with hospitals, clinics, and physician's practices.
Let's not forget that our CFO stated that, "our balance sheet will look dramatically different" and that upgrades will be forthcoming as you can see by the report Griffin Securities published 8-11-14 discussing the partnership and a $16.25 price target.
Medicare policy enables clinicians to charge $35 for the spirometry or lung test. $35 might not seem like much, but this is a significant percentage of an average physician visit. Hence, clinicians will indeed be inclined to prescribe Afrezza "en masse" in facing increasing working hours and decreasing reimbursement from Medicare and insurance companies. The added revenues from Afrezza and spirometry will increase clinics' revenues and will help to offset their declining income. After all, physicians still have to pay their staffs and overhead costs despite receiving lower insurance compensation.
Published: Friday, 15 August 2014 22:17 Written by Doctor Hung V. Tran, MD, MS
Disclosure: I am long on MNKD.
360 Biotech Catalyst Keys
In contrast to the notion that the required lung testing or PFT is cumbersome and could hamper Afrezza sales, the test is quick and simple to perform with minimal discomfort to patients
Primary care settings such as clinics and physician offices already have at least one spirometer, which is commonly use to check lungs function for patients with asthma or COPD
Hospitals, clinics, and physicians’ offices facing reduced insurance compensations will appreciate being able to offset their declining income by billing for the test.
The Story. Despite significant improvements on the stock's fundamentals, many short contingents are still highly negative on the company. Prior to the FDA Advisory Committee (ADCOM) meeting on April 1, 2014, Adam Feuerstein a senior columnist of The Street prognosticated that MannKind will failed to received recommendation from the ADCOM. Needless to say, the ADCOM experts consist of physicians, scientists, industry leaders, and patients advocate voted 14-0 and 13-1 with high recommendation for Afrezza as treatment indications for both Type 1 and Type 2 diabetes, respectively. While it might seem an honorable act that Mr. Feuerstein apologized for his faulty prediction, it is rather hypocrisy because the senior columnist continues to attack MannKind. After the ADCOM, Mr. Feuerstein then stated with 60 percent confident that the FDA will not approved Afrezza. Contrary to his misguided journalism, the FDA approved Afrezza on June 27, 2014, for both Type 1 and Type 2 diabetes. It appeared that something never changes!
The short contingent once again attempted to spin the facts even after the FDA approval. This time it is Afrezza's FDA labeling requirement, which states that prescribers "need to evaluate all patients for lung disease such as asthma or COPD before starting Afrezza. Before initiating Afrezza, perform a detail medical history, physical examination, and spirometry (FEV1)."
Interestingly, the short contingent claims that lung testing would hamper Afrezza's sales based on his knowledge of medicine, which amounts to several college courses on biology. While that is amusing to physicians, our research shows that spirometry will actually motivates clinicians to prescribe Afrezza "en mass" in hospitals, physicians’ offices and clinics.